Tirabrutinib
- Generic Name
- Tirabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N6O3
- CAS Number
- 1351636-18-4
- Unique Ingredient Identifier
- LXG44NDL2T
- Background
Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Phase 1
Terminated
- Conditions
- B-cell Malignancies
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 203
- Registration Number
- NCT02457598
- Locations
- 🇬🇧
Cardiff and Vale Health Board, Clinical Research Facility, Cardiff, United Kingdom
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
Phase 1
Completed
- Conditions
- Non Hodgkins LymphomaChronic Lymphocytic Leukaemia
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01659255
- Locations
- 🇫🇷
CHU St Eloi, Montpellier, France
🇫🇷CHRU - Hopital Claude HURIEZ, Lille, France
🇫🇷Centre hospitalier Lyon Sud, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath